Far East Bio-Tec Co., Ltd.
Far East Bio-Tec Co., Ltd. manufactures and sells organic chlorella, spirulina, and dietary supplements. It also offers nutraceuticals/nutritional supplements, immune booster products, antiviral sprays, and pet supplements. The company was founded in 1976 and is based in Taipei, Taiwan.
Far East Bio-Tec Co., Ltd. (6886) - Total Liabilities
Latest total liabilities as of June 2025: NT$135.59 Million TWD
Based on the latest financial reports, Far East Bio-Tec Co., Ltd. (6886) has total liabilities worth NT$135.59 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Far East Bio-Tec Co., Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how Far East Bio-Tec Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Far East Bio-Tec Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Far East Bio-Tec Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UNITIKA
BE:UTN
|
Germany | €148.09 Billion |
|
Hortico S.A.
WAR:HOR
|
Poland | zł49.79 Million |
|
KINGDEE INTL SOFTWA
BE:KDIC
|
Germany | €5.44 Billion |
|
Eleco PLC
LSE:ELCO
|
UK | GBX25.62 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Far East Bio-Tec Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Far East Bio-Tec Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Far East Bio-Tec Co., Ltd. (2020–2024)
The table below shows the annual total liabilities of Far East Bio-Tec Co., Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$127.50 Million | +57.68% |
| 2023-12-31 | NT$80.86 Million | -29.22% |
| 2022-12-31 | NT$114.24 Million | +16.72% |
| 2021-12-31 | NT$97.88 Million | +2.08% |
| 2020-12-31 | NT$95.88 Million | -- |